BioAtla, Inc. (BCAB)

Market Cap	22.68M
Revenue (ttm)	11.00M
Net Income (ttm)	-61.88M
Shares Out	58.42M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	438,404
Open	0.3800
Previous Close	0.3866
Day's Range	0.3800 - 0.3920
52-Week Range	0.2400 - 2.5250
Beta	0.90
Analysts	Buy
Price Target	1.00 (+157.6%)
Earnings Date	Aug 7, 2025

About BCAB

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 16, 2020
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: BCAB
• Website: https://www.bioatla.com

Analyst Summary

According to 2 analysts, the average rating for BCAB stock is "Buy." The 12-month stock price target is $1.0, which is an increase of 157.60% from the latest price.

Price Target

$1.0

(157.60% upside)

Analyst Consensus: Buy